Año 2019 / Volumen 111 / Número 12
Original
Elevated serum levels of interleukin-37 correlate with poor prognosis in gastric cancer

941-945

DOI: 10.17235/reed.2019.6460/2019

Yan Zhang, Min Tang, Xiao-Ge Wang, Jin-Hua Gu, Li-Na Zhou, Jun Jin, Ping Li, Li-Qiang Wang, Min-Bin Chen,

Resumen
Background: interleukin-37 (IL-37) is as a natural suppressor of the innate inflammatory and immune responses. It has also been reported to be involved in carcinogenesis and metastasis. The present case-control study was designed to investigate the role of serum levels of IL-37 in patients with gastric cancer. Methods: serum IL-37 levels were determined using the enzyme-linked immunosorbent assay in 180 patients diagnosed with gastric cancer and 100 healthy controls. The association between IL-37 levels and clinical factors was assessed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these parameters in gastric cancer. Results: serum IL-37 levels in gastric cancer patients (5.606 ± 0.837 pg/ml) were significantly higher than those in healthy controls (2.364 ± 0.210 pg/ml, p < 0.001). High serum IL-37 levels were related to a poorly differentiated histologic type (p = 0.046) and advanced T stage (p = 0.003). The Kaplan-Meier survival analysis indicated that the high-IL-37 group had a poorer overall survival and progression-free survival (overall survival [OS]: 39.0 months vs 13.0 months, p < 0.001, progression-free survival [PFS]: 25.0 months vs 10.0 months, p < 0.001). Multivariate analyses showed serum IL-37 to be an independent prognostic factor for gastric cancer patients (OS: hazard ratios [HR] = 1.842, 95% CI: 1.190-2.854, p = 0.006; PFS: HR = 1.547, 95% CI: 1.014-2.359, p = 0.043). Conclusions: in conclusion, serum IL-37 levels were associated with poor overall survival and progression-free survival in gastric cancer patients. IL-37 may be a potential predictor of prognosis in gastric cancer.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
2. Xu G, Feng F, Liu S, et al. Clinicopathological features and prognosis in elderly gastric cancer patients: a retrospective cohort study. OncoTargets and therapy. 2018;11:1353-62.
3. Chen HM, Fujita M. IL-37: a new player in immune tolerance. Cytokine. 2015;72(1):113-4.
4. Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunological reviews. 2018;281(1):179-90.
5. Li S, Neff CP, Barber K, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(8):2497-502.
6. Ballak DB, van Diepen JA, Moschen AR, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nature communications. 2014;5:4711.
7. Conti P, Gallenga CE, Ronconi G, et al. Activation of mast cells mediates inflammatory response in psoriasis: Potential new therapeutic approach with IL-37. Dermatologic therapy. 2019:e12943.
8. Li Y, Wang Z, Yu T, et al. Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PloS one. 2014;9(9):e107183.
9. Chen B, Huang K, Ye L, et al. Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. Journal of translational medicine. 2015;13:36.
10. Ding VA, Zhu Z, Xiao H, et al. The role of IL-37 in cancer. Medical oncology. 2016;33(7):68.
11. Huo J, Hu J, Liu G, et al. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients. Archives of gynecology and obstetrics. 2017;295(2):459-65.
12. Jiang Y, Wang Y, Liang L, et al. IL-37 mediates the antitumor activity in renal cell carcinoma. Medical oncology. 2015;32(11):250.
13. Jia H, Liu J, Han B. Reviews of Interleukin-37: Functions, Receptors, and Roles in Diseases. BioMed research international. 2018;2018:3058640.
14. Yang L, Zhang J, Tao J, et al. Elevated serum levels of Interleukin-37 are associated with inflammatory cytokines and disease activity in rheumatoid arthritis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2015;123(12):1025-31.
15. Farrokhi M, Rezaei A, Amani-Beni A, et al. Increased serum level of IL-37 in patients with multiple sclerosis and neuromyelitis optica. Acta neurologica Belgica. 2015;115(4):609-14.
16. Zhao JJ, Pan QZ, Pan K, et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Scientific reports. 2014;4:5177.
17. Jiang M, Wang Y, Zhang H, et al. IL-37 inhibits invasion and metastasis in non-small cell lung cancer by suppressing the IL-6/STAT3 signaling pathway. Thoracic cancer. 2018;9(5):621-9.
18. Shuai X, Wei-min L, Tong YL, et al. Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells. Scientific reports. 2015;5:14478.
19. Wu W, Wang W, Wang Y, et al. IL-37b suppresses T cell priming by modulating dendritic cell maturation and cytokine production via dampening ERK/NF-kappaB/S6K signalings. Acta biochimica et biophysica Sinica. 2015;47(8):597-603.
20. von Boehmer H, Daniel C. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nature reviews Drug discovery. 2013;12(1):51-63.
Artículos relacionados

Carta

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Revisión

Inmunoterapia en el carcinoma hepatocelular

DOI: 10.17235/reed.2022.8876/2022

Imagen en Patología Digestiva

Atrofia vellosa intestinal, un reto endoscópico diagnóstico

DOI: 10.17235/reed.2021.8169/2021

Carta

Hepatitis autoinmune desencadenada por la COVID-19

DOI: 10.17235/reed.2021.8045/2021

Revisión

Practical management of primary biliary cholangitis

DOI: 10.17235/reed.2021.8219/2021

Original

Can we optimize CEA as a response marker in rectal cancer?

DOI: 10.17235/reed.2020.7321/2020

Carta

Hepatitis aguda por olmesartán: una entidad infrecuente

DOI: 10.17235/reed.2020.7236/2020

Original

Diarrea crónica secundaria a enteropatía autoinmune

DOI: 10.17235/reed.2020.7218/2020

Carta

Primary squamous cell carcinoma of the stomach: a rare entity

DOI: 10.17235/reed.2018.5900/2018

Editorial

El reto del colon derecho

DOI: 10.17235/reed.2018.5544/2018

Imagen en Patología Digestiva

Immune mediated colitis caused by lung cancer treatment with atezolizumab

DOI: 10.17235/reed.2017.5060/2017

Carta al Editor

Tumores neuroendocrinos de páncreas: claves para afrontar la heterogeneidad

DOI: 10.17235/reed.2017.4997/2017

Carta al Editor

Tumores neuroendocrinos de páncreas: factores pronósticos

DOI: 10.17235/reed.2017.5109/2017

Editorial

Tumores neuroendocrinos del páncreas: no tan raros y no tan benignos

DOI: 10.17235/reed.2016.4672/2016

Caso Clínico

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Instrucciones para citar
Zhang Y, Tang M, Wang X, Gu J, Zhou L, Jin J, et all. Elevated serum levels of interleukin-37 correlate with poor prognosis in gastric cancer. 6460/2019


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 771 veces.
Este artículo ha sido descargado 176 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 22/06/2019

Aceptado: 31/07/2019

Prepublicado: 13/11/2019

Publicado: 05/12/2019

Tiempo de revisión del artículo: 33 días

Tiempo de prepublicación: 144 días

Tiempo de edición del artículo: 166 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas